# Henry Schein (HSIC) Financial Model Free Excel 3-statement financial model and company analysis for Henry Schein. - Canonical: https://finamodel.com/companies/henry-schein - Industry: Healthcare Services - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/HSIC.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool to evaluate whether Henry Schein's strategic shift towards higher-margin technology and specialty products (the BOLD+1 plan) will offset gross margin pressures in its core distribution business. ## Company Overview Henry Schein, Inc. is the world's largest provider of health care solutions to office-based dental and medical practitioners. The company operates a vast global supply chain network, distributing over 300,000 products, while increasingly pivoting towards high-margin software, e-services, and specialty medical devices. Business segments (based on the 2024/2025 reporting structure): * **Global Distribution and Value-Added Services** (approx. 82-85% of revenue): Dental and medical merchandise, equipment sales, and practice transition services. * **Global Specialty Products** (approx. 10-11% of revenue): Dental implants, biomaterials, endodontic, and orthodontic products. * **Global Technology** (approx. 4-5% of revenue): Practice management software (Dentrix Ascend, Dentally) and related e-services. Key geographies include North America (majority of revenue), Europe, and Australasia. The business model is primarily an asset-light distribution model, augmented by a rapidly growing, high-margin subscription software business. Henry Schein holds the number one market share position in dental distribution in the US, Canada, Europe, Australia, and Brazil. Recent major events include a significant restructuring programme initiated in August 2024, a cyber incident in late 2023 that impacted early 2024 comparables, the ongoing BOLD+1 strategic plan targeting over 50% of operating income from high-growth segments by 2027, and a CEO transition to Fred Lowery in early 2026. ## Revenue Deep Dive ### Global Distribution and Value-Added Services * **Segment name**: Global Distribution and Value-Added Services * **Revenue driver formula**: Active Customers x Average Order Value x Order Frequency * **Historical growth rate**: 2% to 4% CAGR. * **Key growth levers and headwinds**: Driven by patient traffic to dental and medical offices. Headwinds include macroeconomic sensitivity in elective dental procedures and product mix shifts towards lower-margin value categories. * **Pricing dynamics**: Highly competitive, spot pricing for consumables, with negotiated contracts for large group practices and government accounts. * **Revenue recognition notes**: Recognised upon delivery of products. * **Seasonality**: Q4 is typically the strongest quarter due to year-end equipment purchases by practitioners seeking tax benefits, while Q3 sees a bump from medical flu vaccine sales. ### Global Specialty Products * **Segment name**: Global Specialty Products * **Revenue driver formula**: Procedure Volume x Average Selling Price per Unit (Implants/Biomaterials) * **Historical growth rate**: 4% to 6% CAGR. * **Key growth levers and headwinds**: Driven by an ageing population requiring restorative dentistry. Headwinds include consumer pushback on high-cost implant procedures during economic downturns. * **Pricing dynamics**: Premium pricing for proprietary implants, though the company is intentionally expanding its "value implant" portfolio to capture market share. * **Revenue recognition notes**: Recognised upon shipment or delivery. * **Seasonality**: Relatively smooth, with slight dips in summer months when patients defer major dental work. ### Global Technology * **Segment name**: Global Technology * **Revenue driver formula**: Software Subscribers x Annual Revenue Per User (ARPU) * **Historical growth rate**: 8% to 10% CAGR (cloud solutions growing double-digits). * **Key growth levers and headwinds**: Accelerated adoption of cloud-based practice management software (Dentrix Ascend in the US, Dentally internationally). Headwinds include the high switching costs for dental practices moving off legacy on-premise systems. * **Pricing dynamics**: Subscription-based recurring revenue with high pricing power and low churn. * **Revenue recognition notes**: Subscription revenue is recognised rateably over the contract term; deferred revenue is recorded for upfront payments. * **Seasonality**: Non-seasonal due to the recurring subscription model. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown**: Cost of products sold, inbound freight charges, and purchasing costs. * **Gross margin range**: 30.5% to 31.5% over the last 5 years. * **Key input costs and commodity exposures**: Fuel costs for freight, raw material costs for manufactured specialty products, and wholesale pricing from third-party manufacturers (e.g., 3M, Dentsply Sirona). * **How COGS scales with revenue**: Highly linear for the distribution segment. However, as the Technology segment grows, consolidated gross margin should theoretically expand due to the near-zero marginal cost of software. ### Operating Expenses * **R&D**: Minimal as a percentage of total revenue (less than 1%), primarily focused on the Global Technology and Specialty Products segments. * **SG&A**: Represents the bulk of operating expenses (approx. 23% to 24% of revenue). Includes distribution centre operations, sales commissions, marketing, and corporate overhead. * **Depreciation & Amortisation**: Approx. 1.5% to 2.0% of revenue, heavily weighted towards amortisation of acquired intangibles due to the company's serial bolt-on acquisition strategy. * **Stock-Based Compensation**: Approx. 0.5% of revenue. * **Restructuring / one-time charges**: Frequent. The company recorded approximately $105 million in restructuring expenses in 2025 tied to an August 2024 programme, which will continue into 2026 and 2027. ### Margin Profile * **Gross margin**: 30.5% to 31.5%. Recently contracted slightly (down approx. 19 to 56 bps in recent quarters) due to a mix shift towards lower-margin value implants and distribution products. * **EBITDA margin**: 8.0% to 8.5% (Adjusted EBITDA was $1,101 million on $13.2 billion sales in 2025, approx. 8.3%). * **Operating margin**: GAAP operating margin sits around 4.7% to 4.9%, while non-GAAP operating margin is consistently between 7.4% and 7.8%. * **Margin trend**: GAAP margins are currently compressed due to restructuring costs. Non-GAAP margins are stable, with management targeting over $200 million in operating income improvements over the next few years. ## Balance Sheet Structure * **Total assets**: Approximately $9 billion to $10 billion. * **Key asset categories**: Accounts receivable and inventory make up the vast majority of tangible assets, reflecting the working-capital-intensive nature of distribution. * **Goodwill & intangibles**: Represents over 30% of total assets, driven by decades of continuous bolt-on acquisitions. * **Working capital profile**: * **Days Sales Outstanding (DSO)**: 40 to 45 days. * **Days Inventory Outstanding (DIO)**: 55 to 65 days. * **Days Payable Outstanding (DPO)**: 45 to 55 days. * **Net working capital as % of revenue**: Approximately 10% to 12%. * **Working capital funding**: Working capital is positive and represents a use of cash as the business grows. * **PP&E**: Relatively small (approx. 5% to 7% of assets), consisting of distribution centres, office facilities, and computer equipment. Useful lives range from 3 to 15 years for equipment and up to 40 years for buildings. * **Right-of-use assets**: Material due to leased distribution centres and office spaces globally. ## Capital Expenditure & Investment * **Capex as % of revenue**: Very light, typically 0.5% to 1.0% of revenue (e.g., $33 million in Q3 2025 on a $3.34 billion revenue base). * **Maintenance vs. growth capex**: Roughly 60% maintenance (facility upkeep, IT hardware) and 40% growth (warehouse automation, software development). * **Capitalised software**: Material for the Global Technology segment as they build out Dentrix Ascend and Dentally cloud platforms. * **M&A pattern**: Serial bolt-on acquirer. The company routinely spends $100 million to $300 million annually acquiring regional distributors, specialty manufacturers, and software add-ons. * **Typical acquisition multiple**: 10x to 14x EBITDA for specialty and technology assets; lower for traditional distribution. ## Debt & Capital Structure * **Total debt**: Approximately $3.0 billion to $3.5 billion. * **Debt/EBITDA ratio**: Currently sits around 2.7x, consistent with their investment-grade balance sheet strategy. * **Credit rating**: Investment grade (typically BBB+ or equivalent). * **Key debt instruments**: Unsecured senior notes, a large revolving credit facility, and term loans. * **Interest rate profile**: A mix of fixed-rate bonds and floating-rate bank debt. * **Share repurchase programme**: Highly active. The company repurchased $850 million of stock in 2025 (approx. 12.1 million shares) and has $780 million remaining under its current authorisation. * **Dividend policy**: Henry Schein does not pay a dividend, preferring to return capital exclusively through share repurchases. ## Cash Flow Characteristics * **Operating cash flow conversion**: Strong. OCF was $712 million in 2025 and $848 million in 2024. * **Free cash flow margin**: Typically 5% to 7% of revenue. * **Major non-cash items**: Depreciation, amortisation of acquired intangibles, stock-based compensation, and deferred tax provisions. * **Working capital cash flow impact**: Inventory build-ups ahead of the Q4 busy season act as a use of cash in Q3, reversing in Q1 of the following year. * **Capex intensity**: Extremely low, allowing for high free cash flow conversion. * **Cash tax rate**: The non-GAAP effective tax rate is approximately 23.7% to 25.0%. ## Sheet Structure 1. **Assumptions**: Hardcoded drivers for macroeconomic inputs, segment growth rates, margin profiles, working capital days, and capital allocation targets. 2. **Scenarios**: Scenario manager toggling between Base, Bull (rapid BOLD+1 execution), and Bear (prolonged dental market softness). 3. **Revenue Build**: Detailed build for Global Distribution, Global Specialty Products, and Global Technology, forecasting volume and pricing/ARPU trends. 4. **Income Statement**: Consolidated P&L mirroring the 10-K, including specific lines for Restructuring Costs and Amortisation of Acquired Intangibles. 5. **Working Capital**: Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO. 6. **Depreciation & Amortisation**: Waterfall schedules for existing PP&E, new Capex, and acquired intangibles. 7. **Debt Schedule**: Tranche-by-tranche debt build, tracking the revolving credit facility, term loans, senior notes, and interest expense calculations. 8. **Shareholders Equity**: Tracking retained earnings, stock-based compensation, and the aggressive share repurchase programme. 9. **Balance Sheet**: Standard balancing statement. 10. **Cash Flow Statement**: Indirect method starting from Net Income, adjusting for non-cash items and working capital changes. 11. **DCF Valuation**: Unlevered free cash flow build, WACC calculation, and terminal value using the perpetuity growth method. 12. **Outputs & Charts**: Summary dashboard showing EPS growth, Adjusted EBITDA margins, and segment revenue mix over time. ## Key Financial Relationships 1. Global Distribution Revenue = Prior Year Global Distribution Revenue x (1 + Distribution Volume Growth + Distribution Price/Mix Growth + FX Impact) 2. Global Specialty Revenue = Prior Year Global Specialty Revenue x (1 + Specialty Volume Growth + Specialty Price/Mix Growth + FX Impact) 3. Global Technology Revenue = Prior Year Global Technology Revenue x (1 + Software Subscriber Growth + ARPU Growth + FX Impact) 4. Consolidated Net Sales = Global Distribution Revenue + Global Specialty Revenue + Global Technology Revenue 5. Cost of Sales = Consolidated Net Sales x (1 - Consolidated Gross Margin %) 6. Gross Profit = Consolidated Net Sales - Cost of Sales 7. SG&A Expense = Consolidated Net Sales x SG&A % of Revenue 8. Adjusted EBITDA = Gross Profit - SG&A Expense (excluding stock-based comp and restructuring) 9. Accounts Receivable = (Consolidated Net Sales / 365) x DSO 10. Inventory = (Cost of Sales / 365) x DIO 11. Accounts Payable = (Cost of Sales / 365) x DPO 12. Share Repurchase Outflow = Available Free Cash Flow x Target Repurchase % 13. Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchase Outflow / Average Share Price) 14. Non-GAAP EPS = (Net Income + Amortisation of Intangibles + Restructuring Costs) / Ending Shares Outstanding ## Cross-Sheet Dependencies * The **Assumptions** sheet dictates the growth rates and margin profiles used in the **Revenue Build** and **Income Statement**. * The **Income Statement** generates Net Income, which flows to the top of the **Cash Flow Statement** and feeds Retained Earnings on the **Balance Sheet**. * The **Working Capital** sheet uses Revenue and COGS from the **Income Statement** to calculate balances, which flow to the **Balance Sheet** and create cash adjustments on the **Cash Flow Statement**. * The **Debt Schedule** uses the cash surplus/deficit from the **Cash Flow Statement** to pay down or draw on the revolver. The resulting interest expense flows back to the **Income Statement** (creating a circular reference that must be managed with a toggle). * The **Shareholders Equity** sheet calculates share repurchases based on cash flow, which reduces the share count used for EPS calculations on the **Income Statement**. ## Sign Convention * Revenue, Gross Profit, and Net Income are shown as positive numbers. * Expenses (COGS, SG&A, Interest Expense, Taxes) are shown as positive numbers in their specific schedules but subtracted in summation formulas (e.g., Gross Profit = Revenue - COGS). * On the Cash Flow Statement, cash inflows (e.g., net income, depreciation, increases in payables) are positive. Cash outflows (e.g., capex, increases in inventory, share repurchases) are negative. * Debt paydowns are negative; debt drawdowns are positive. ## Things Most Likely to Go Wrong 1. **Segment Restatement**: The company changed its segment reporting structure in 2024/2025 to the three new groups (Distribution, Specialty, Technology). Historical data prior to 2024 must be manually recast using Exhibit D from their Q4 2024 earnings release; failure to do so will break trend analysis. 2. **GAAP vs. Non-GAAP Disconnect**: Henry Schein has massive differences between GAAP and Non-GAAP EPS due to continuous restructuring charges and acquisition-related amortisation. The model must explicitly build both to match consensus estimates. 3. **Gross Margin Mix Shift**: Assuming a flat gross margin will overstate profitability. The model must account for the mix shift towards lower-margin value implants and distribution products, which has recently compressed gross margins by 19 to 56 bps. 4. **Share Count Reduction**: The company repurchased 12.1 million shares in 2025 alone. Failing to model aggressive ongoing share repurchases will severely understate future EPS. 5. **FX Volatility**: With operations in 34 countries, foreign exchange swings routinely impact revenue by 1% to 2% annually. The model should separate constant-currency growth from FX impacts. 6. **Restructuring Add-backs**: The August 2024 restructuring programme extends into 2026 and 2027. These costs must be modelled as operating expenses for GAAP purposes but added back for Adjusted EBITDA and Non-GAAP EPS calculations. 7. **Cyber Incident Base Effects**: Late 2023 and early 2024 results were distorted by a major cyber incident. Year-over-year growth rates for 2025 look artificially high in certain quarters due to this weak base; normalise growth rates for 2026 onwards. 8. **Seasonality in Working Capital**: Q4 is the strongest sales quarter, leading to a spike in year-end accounts receivable that unwinds in Q1. Annual models will mask this, but quarterly models must capture the working capital swing. ## Validation Checks 1. Consolidated Gross Margin should remain between 30.0% and 31.5%; flag if it falls outside this band. 2. Non-GAAP Operating Margin should be in the 7.4% to 7.8% range based on recent historical performance. 3. Capex as a percentage of revenue must not exceed 1.0% (the business is highly asset-light). 4. Debt/EBITDA should remain near the target of 2.7x; flag if it exceeds 3.0x, as this would violate management's investment-grade strategy. 5. The Balance Sheet must balance perfectly in every period (Total Assets = Total Liabilities + Shareholders Equity). 6. Total sales growth for 2026 should align with management guidance of 3% to 5%. 7. Non-GAAP effective tax rate should be between 23.5% and 25.0%. 8. Share count must decrease year-over-year, reflecting the active $780 million repurchase authorisation. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Global Distribution Revenue Growth | 3.5% | % | Midpoint of historical core growth and 2026 guidance. | | Global Specialty Revenue Growth | 5.0% | % | Reflects higher growth profile of implants and biomaterials. | | Global Technology Revenue Growth | 8.0% | % | Reflects strong double-digit growth in cloud software offset by legacy systems. | | Consolidated Gross Margin | 30.9% | % | Matches Q4 2025 actuals, reflecting recent mix-driven compression. | | SG&A as % of Revenue | 23.5% | % | Calculated to bridge 30.9% gross margin to ~7.4% non-GAAP operating margin. | | Restructuring Costs (2026) | 50.0 | $M | Estimated run-rate for the continuation of the 2024/2025 programme. | | DSO (Days Sales Outstanding) | 42 | Days | Based on historical average of accounts receivable turnover. | | DIO (Days Inventory Outstanding) | 60 | Days | Based on historical average of inventory turnover. | | DPO (Days Payable Outstanding) | 50 | Days | Based on historical average of accounts payable turnover. | | Capex as % of Revenue | 0.8% | % | Reflects asset-light model and recent historical averages. | | Effective Tax Rate (Non-GAAP) | 24.0% | % | Midpoint of management's 2025/2026 guidance range (23.7% - 25.0%). | | Annual Share Repurchases | 400.0 | $M | Conservative estimate based on $780M remaining authorisation and historical run-rate. | | Average Interest Rate on Debt | 5.5% | % | Blended rate of fixed senior notes and floating revolver debt. | | WACC | 8.0% | % | Standard discount rate for a stable, investment-grade healthcare distributor. | | Terminal Growth Rate | 2.0% | % | Aligns with long-term GDP and inflation expectations. | ## Data Sources & Benchmarks * **Filings**: SEC EDGAR (Form 10-K, 10-Q, 8-K) and the Henry Schein Investor Relations website (investor.henryschein.com). * **Key Peers**: Patterson Companies (PDCO), McKesson (MCK), Cencora (COR), Cardinal Health (CAH), and Align Technology (ALGN) for the specialty dental segment. * **Industry Data**: American Dental Association (ADA) for dental patient traffic and procedure volumes; Centers for Medicare & Medicaid Services (CMS) for broader healthcare spending trends. * **Consensus Estimates**: FactSet or Bloomberg for forward-looking EPS and revenue consensus to validate model outputs. ## Sources * Henry Schein Q4 2025 Earnings Release and Financial Results. * Henry Schein Q3 2025 Earnings Call Transcripts and Presentations. * Henry Schein 2024/2025 Segment Restatement Announcements. * Analyst reports and financial news summaries regarding margin pressures and restructuring. * SEC Form 10-K and 10-Q filings for historical balance sheet and cash flow data. --- ## Frequently asked questions ### What does Henry Schein do? Henry Schein, Inc. is the world's largest provider of health care solutions for office-based dental and medical practitioners. The company distributes over 300,000 products and is increasingly focusing on high-margin software, e-services, and specialty medical devices. Its main business segments include Global Distribution, Global Specialty Products, and Global Technology. ### What are the primary revenue drivers for Henry Schein? Henry Schein's revenue is primarily driven by its vast global supply chain network distributing dental and medical products. Growth is also increasingly fueled by its strategic pivot towards higher-margin technology solutions like practice management software and specialty medical devices, as outlined in its BOLD+1 plan. The company also holds significant market share in dental distribution across key geographies. ### What are the key financial model assumptions for Henry Schein's growth and margins? Key assumptions in a financial model for Henry Schein include an annual revenue growth rate of approximately 5.4%. The model also assumes a cost of goods sold at roughly 70% of revenue and selling, general, and administrative expenses at about 22.3% of revenue. These assumptions help evaluate the company's profitability and operational efficiency. ### How does Henry Schein's strategic shift impact its gross margins? Henry Schein's strategic shift, known as the BOLD+1 plan, aims to pivot towards higher-margin technology and specialty products. This initiative is designed to offset gross margin pressures experienced in its core distribution business. The financial model evaluates whether this shift will successfully enhance overall profitability. ### What is the forecast horizon for the Henry Schein financial model? The Henry Schein financial model provides a comprehensive forecast horizon spanning from Fiscal Year 2026 through Fiscal Year 2030. This extended period allows for a detailed analysis of the company's financial performance and strategic initiatives. The model is designed for equity valuation and scenario planning. ### Can I download an Excel financial model for Henry Schein? Yes, an Excel financial model for Henry Schein is available for download. This general corporate model provides tools for comprehensive equity valuation and scenario planning. It allows users to evaluate the impact of Henry Schein's strategic shift on its financial performance. [Interactive forecast calculator](https://finamodel.com/companies/henry-schein/forecast)